Cowealth Medical Holding Co (ROCO:4745) 1-Year Sharpe Ratio: -0.25 (As of Sep. 12, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:4745 Cowealth Medical Holding Co Ltd ROCO:4745
53 GF Score
Price NT$11.70
GF Value NT$14.11
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Cowealth Medical Holding Co 1-Year Sharpe Ratio?

Cowealth Medical Holding Co ROCO:4745 -0.43% 53 1-Year Sharpe Ratio is -0.25 as of Sep. 12, 2026. GuruFocus rates ROCO:4745 with a GF Score™ of 53/100 and a GF Value™ of NT$14.11 (Modestly Undervalued). The stock has 5 warning signs investors should review.

The 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk over the past year. As of today (2026-09-12), Cowealth Medical Holding Co's 1-Year Sharpe Ratio is -0.25.


Cowealth Medical Holding Co  (ROCO:4745) 1-Year Sharpe Ratio Explanation

The 1-Year Sharpe Ratio inidicates the risk-adjusted return of an investment over the past year. It is calculated as the annualized result of the average monthly excess return divided by its standard deviation over the past year. The monthly excess return is the monthly investment return minus the monthly risk-free rate (typically the 10-year Treasury Constant Maturity Rate). If the risk-free rate for a specific region is not available, U.S. data is used by default.

The greater a portfolio's Sharpe Ratio, the better its risk-adjusted performance. A negative Sharpe Ratio means the risk-free rate is greater than the portfolio’s historical or projected return, or else the portfolio's return is expected to be negative.


Cowealth Medical Holding Co 1-Year Sharpe Ratio Related Terms


ROCO:4745 vs ABT, SYK, MDT: 1-Year Sharpe Ratio Comparison

For the Medical Devices subindustry, Cowealth Medical Holding Co's 1-Year Sharpe Ratio, along with its competitors' market caps and 1-Year Sharpe Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cowealth Medical Holding Co 1-Year Sharpe Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cowealth Medical Holding Co's 1-Year Sharpe Ratio distribution charts can be found below:

* The bar in red indicates where Cowealth Medical Holding Co's 1-Year Sharpe Ratio falls into.


ROCO:4745
53GF Score
Cowealth Medical Holding Co Ltd ROCO:4745
1-Year Sharpe Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cowealth Medical Holding Co 1-Year Sharpe Ratio Calculation

The 1-Year Sharpe Ratio measures the performance of an investment such as a stock or portfolio compared to a risk-free asset. A stock / portfolio's 1-Year Sharpe Ratio can be calculated by dividing the difference between the one-year returns of the investment and the risk-free rate, by the standard deviation of the investment returns over one year.

Frequently Asked Questions Learn more about 1-Year Sharpe Ratio →
What does a 1-Year Sharpe Ratio of -0.25 mean?
Cowealth Medical Holding Co (ROCO:4745) has a 1-Year Sharpe Ratio of -0.25 as of Sep. 12, 2026. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Cowealth Medical Holding Co and its competitors.
Is Cowealth Medical Holding Co's 1-Year Sharpe Ratio too high?
Cowealth Medical Holding Co's current 1-Year Sharpe Ratio is -0.25. Overall, Cowealth Medical Holding Co has a GF Score™ of 53/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cowealth Medical Holding Co's 1-Year Sharpe Ratio compare to ABT and SYK?
Cowealth Medical Holding Co's 1-Year Sharpe Ratio of -0.25 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 1-Year Sharpe Ratio for a Medical Devices & Instruments company?
A good 1-Year Sharpe Ratio depends on the Medical Devices & Instruments industry context. However, 1-Year Sharpe Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 1-Year Sharpe Ratio mean?
A high 1-Year Sharpe Ratio can signal that a stock is expensive relative to its fundamentals. 1-Year Sharpe Ratio measures the additional return that an investor receives per unit of increase in risk. View historical data for Cowealth Medical Holding Co and its competitors. Cowealth Medical Holding Co's current 1-Year Sharpe Ratio is -0.25. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cowealth Medical Holding Co stock overvalued right now?
Based on GuruFocus' analysis, Cowealth Medical Holding Co (ROCO:4745) is currently considered Modestly Undervalued. The stock's GF Value™ is NT$14.11, compared to a current price of NT$11.70 — trading 17.1% below its estimated fair value. The current 1-Year Sharpe Ratio is -0.25. Cowealth Medical Holding Co's overall GF Score™ is 53/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 1-Year Sharpe Ratio calculated?
1-Year Sharpe Ratio is calculated from a company's financial statements. For Cowealth Medical Holding Co (ROCO:4745), the current 1-Year Sharpe Ratio is -0.25 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cowealth Medical Holding Co (ROCO:4745) Overvalued in 2026?

Based on GuruFocus' analysis, Cowealth Medical Holding Co stock appears to be undervalued. The current stock price of NT$11.70 is trading 17.1% below its estimated GF Value™ of NT$14.11. GuruFocus considers Cowealth Medical Holding Co to be Modestly Undervalued.

Key valuation signals for ROCO:4745:

  • 1-Year Sharpe Ratio: -0.25
  • GF Value™: NT$14.11 vs. price of NT$11.70 (17.1% below fair value)
  • GF Score™: 53/100 with 5 warning signs

No single metric tells the full story. See the ROCO:4745 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Cowealth Medical Holding Co Business Description

Address North Sound Road, Suite 102, Cannon Place, P.O. Box 712, George Town, Grand Cayman, CYM, KY1-9006
Cowealth Medical Holding Co Ltd is mainly involved in trading medical equipment, reagents, and spare parts. Its wide range of solutions includes refined management services tailored for in-vitro diagnostic products, reagents, and consumables, an integrated platform designed for decision-making and analysis, commercialization of achievements in medical science and technology, a Multi-Channel Coaxial Time Audio Video Imaging Platform (MCCTAVIP), and an AI-assisted system for clinical diagnosis. The Group has two reportable segments: Segment A, which generates maximum revenue and sells equipment, and Segment B, which sells reagents and others. Geographically, it generates maximum revenue from China and Hong Kong, and the rest from Taiwan.
53GF Score

Get the complete analysis for ROCO:4745

1-Year Sharpe Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$11.70
Price
NT$14.11
GF Value